Paroxysmal Nocturnal Hemoglobinuria: Current Management, Unmet Needs, and Recommendations

References

• Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253–1258. doi:10.1056/NEJM199511093331904
   PubMed Web of Science ®Google Scholar
• Brodsky RA. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med. 2008;148(8):587–595. doi:10.7326/0003-4819-148-8-200804150-00003
   PubMed Web of Science ®Google Scholar
• Schrezenmeier H, Muus P, Socie G, et al. Baseline characteristics and disease burden in patients in the international paroxysmal nocturnal hemoglobinuria registry. Haematologica. 2014;99(5):922–929. doi:10.3324/haematol.2013.093161
   PubMed Web of Science ®Google Scholar
• Patriquin CJ, Kiss T, Caplan S, et al. How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH Network and review of the national registry. Eur J Haematol. 2019;102(1):36–52. doi:10.1111/ejh.13176
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Craig FE, Digiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010;78(4):211–230. doi:10.1002/cyto.b.20525
   PubMedGoogle Scholar
• Partnering4PNH. A global policy consensus paper to address remaining unmet medical needs for people living with PNH; 2022. Available from: https://pnh.sobi.com/sites/default/files/P4PNH-consensus-paper-short-version%20-%2015.12.2022%20.pdf. Accessed December 02, 2023.
   Google Scholar
• Brodsky RA. Stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica. 2010;95(6):855–856. doi:10.3324/haematol.2010.023176
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica. 2012;97(11):1666–1673. doi:10.3324/haematol.2012.062828
   PubMed Web of Science ®Google Scholar
• Risitano AM, Peffault de Latour R. How we(‘ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol. 2022;196(2):288–303. doi:10.1111/bjh.17753
   PubMed Web of Science ®Google Scholar
• Vallet N, de Fontbrune FS, Loschi M, et al. Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers. Haematologica. 2018;103(3):e103–e105. doi:10.3324/haematol.2017.182360
   PubMedGoogle Scholar
• Heo YA. Pegcetacoplan: a review in paroxysmal nocturnal haemoglobinuria. Drugs. 2022;82(18):1727–1735. doi:10.1007/s40265-022-01809-w
   PubMed Web of Science ®Google Scholar
• Hochsmann B, Peffault de Latour R, Hill A, et al. Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case-control study in the International PNH Registry. Ann Hematol. 2023;102(11):2979–2988. doi:10.1007/s00277-023-05402-3
   PubMed Web of Science ®Google Scholar
• Griffin M, Munir T. Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician’s guide. Ther Adv Hematol. 2017;8(3):119–126. doi:10.1177/2040620716681748
   PubMed Web of Science ®Google Scholar
• Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530–539. doi:10.1182/blood-2018-09-876136
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540–549. doi:10.1182/blood-2018-09-876805
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Brodsky RA, Hill A. Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor. Am J Hematol. 2021;96(7):E232–E235. doi:10.1002/ajh.26176
   PubMed Web of Science ®Google Scholar
• Notaro R, Luzzatto L. Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition. N Engl J Med. 2022;387(2):160–166. doi:10.1056/NEJMra2201664
   PubMed Web of Science ®Google Scholar
• Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2021;137(10):1304–1309. doi:10.1182/blood.2019003812
   PubMed Web of Science ®Google Scholar
• Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol. 2019;10:1157. doi:10.3389/fimmu.2019.01157
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113(17):4094–4100. doi:10.1182/blood-2008-11-189944
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Peffault de Latour R, Rottinghaus ST, et al. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106(1):230–237. doi:10.3324/haematol.2019.236877
   PubMed Web of Science ®Google Scholar
• Harder MJ, Kuhn N, Schrezenmeier H, et al. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood. 2017;129(8):970–980. doi:10.1182/blood-2016-08-732800
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Miura O, Kawaguchi T, et al. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol. 2016;103(6):703–712. doi:10.1007/s12185-016-1946-x
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hochsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373(11):1032–1039. doi:10.1056/NEJMoa1502950
   PubMed Web of Science ®Google Scholar
• Nakayama H, Usuki K, Echizen H, Ogawa R, Orii T. Eculizumab dosing intervals longer than 17 days may be associated with greater risk of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Biol Pharm Bull. 2016;39(2):285–288. doi:10.1248/bpb.b15-00703
   PubMed Web of Science ®Google Scholar
• McKinley CE, Richards SJ, Munir T, et al. Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome. Blood. 2017;130(1):3471.
   Google Scholar
• Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica. 2010;95(4):567–573. doi:10.3324/haematol.2009.007229
   PubMed Web of Science ®Google Scholar
• Rondelli T, Risitano AM, Peffault de Latour R, et al. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2014;99(2):262–266. doi:10.3324/haematol.2013.090001
   PubMed Web of Science ®Google Scholar
• Prata PH, Galimard JE, Sicre de Fontbrune F, et al. Rare germline complement factor H variants in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2023;141(15):1812–1816. doi:10.1182/blood.2022017019
   PubMed Web of Science ®Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632–639. doi:10.1056/NEJMoa1311084
   PubMed Web of Science ®Google Scholar
• Socie G, Caby-Tosi MP, Marantz JL, et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297–310. doi:10.1111/bjh.15790
   PubMed Web of Science ®Google Scholar
• McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–737. doi:10.15585/mmwr.mm6627e1
   PubMed Web of Science ®Google Scholar
• Crew PE, Abara WE, McCulley L, et al. Disseminated gonococcal infections in patients receiving eculizumab: a case series. Clin Infect Dis. 2019;69(4):596–600. doi:10.1093/cid/ciy958
   PubMed Web of Science ®Google Scholar
• Heesterbeek DAC, Angelier ML, Harrison RA, Rooijakkers SHM. Complement and bacterial infections: from molecular mechanisms to therapeutic applications. J Innate Immun. 2018;10(5–6):455–464. doi:10.1159/000491439
   PubMed Web of Science ®Google Scholar
• Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus Eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028–1037. doi:10.1056/NEJMoa2029073
   PubMed Web of Science ®Google Scholar
• Yenerel MN, Sicre de Fontbrune F, Piatek C, et al. Phase 3 study of subcutaneous versus intravenous ravulizumab in eculizumab-experienced adult patients with PNH: primary analysis and 1-year follow-up. Adv Ther. 2023;40(1):211–232. doi:10.1007/s12325-022-02339-3
   PubMed Web of Science ®Google Scholar
• Liu H, Xia L, Weng J, et al. Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): a multicenter, Phase 3, single-arm study. Am J Hematol. 2023;98(9):1407–1414. doi:10.1002/ajh.26998
   PubMed Web of Science ®Google Scholar
• Röth A, He G, Brodsky A, et al. The Phase III, randomized commodore 2 trial: results from a multicenter study of crovalimab vs eculizumab in paroxysmal nocturnal hemoglobinuria (pnh) patients naïve to complement inhibitors. presented at: European Hematology Association; 2023; Frankfurt, Germany. Available from: https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eha/temp/eha23_abstract_bodies/S181.pdf. Accessed December 02, 2023.
   Google Scholar
• Scheinberg P, Cle D, Edwards J, et al. PHASE III randomized, multicenter, open-label commodore 1 trial: comparison of crovalimab vs eculizumab in complement inhibitor-experienced patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). presented at: European Hematology Association; 2023. Available from: https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eha/temp/eha23_abstract_bodies/S183.pdf. Accessed December 02, 2023.
   Google Scholar
• Devalaraja-Narashimha K, Huang C, Cao M, et al. Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PLoS One. 2022;17(6):e0269749. doi:10.1371/journal.pone.0269749
   PubMed Web of Science ®Google Scholar
• Browett PJ, Kulasekararaj A, Notaro R, et al. Vemircopan (ALXN2050) monotherapy in paroxysmal nocturnal hemoglobinuria: interim data from a Phase 2 open-label proof-of-concept study. Blood. 2022;140(2):717–719. doi:10.1182/blood-2022-169301
   Google Scholar
• de Latour RPRA, Kulasekararaj A, Scheinberg P, et al. Oral monotherapy with iptacopan, a proximal complement inhibitor of factor B, has superior efficacy to intravenous terminal complement inhibition with standard of care eculizumab or ravulizumab and favorable safety in patients with paroxysmal nocturnal hemoglobinuria and residual anemia: results from the randomized, active-comparator-controlled, open-label, multicenter, phase III apply-PNH Study. Blood. 2022;140(2). doi:10.1182/blood-2022-171469
   Google Scholar
• Kulasekararaj AG, Lazana I. Paroxysmal nocturnal hemoglobinuria: where are we going. Am J Hematol. 2023;98 Suppl 4:S33–S43. doi:10.1002/ajh.26882.
   PubMed Web of Science ®Google Scholar
• Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020;26(12–b Suppl):S8–S14. doi:10.18553/jmcp.2020.26.12-b.s8
   PubMed Web of Science ®Google Scholar
• Rizzardo S, Bansback N, Dragojlovic N, et al. Evaluating Canadians’ Values for Drug Coverage Decision Making. Value Health. 2019;22(3):362–369. doi:10.1016/j.jval.2018.08.008
   PubMed Web of Science ®Google Scholar
• Lancet Haematology T. The rising cost of orphan drugs. Lancet Haematol. 2015;2(11):e456. doi:10.1016/S2352-3026(15)00229-X
   PubMed Web of Science ®Google Scholar
• Patriquin CJ, Kuo KHM. Eculizumab and beyond: the past, present, and future of complement therapeutics. Transfus Med Rev. 2019;33(4):256–265. doi:10.1016/j.tmrv.2019.09.004
   PubMed Web of Science ®Google Scholar
• Kulagin AD, Ptushkin VV, Lukina EA, et al. Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab. Ann Hematol. 2021;100(11):2689–2698. doi:10.1007/s00277-021-04624-7
   PubMed Web of Science ®Google Scholar
• Jang JH, Gomez RD, Bumbea H, et al. A phase III, randomised, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria. EJHaem. 2023;4(1):26–36. doi:10.1002/jha2.632
   PubMedGoogle Scholar
• Wong RSM, Navarro-Cabrera JR, Comia NS, et al. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2023;7(11):2468–2478. doi:10.1182/bloodadvances.2022009129
   PubMed Web of Science ®Google Scholar
• Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552–559. doi:10.1056/NEJMoa031688
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Brodsky RA, Nishimura JI, Patriquin CJ, Schrezenmeier H. The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2022;13:20406207221091046. doi:10.1177/20406207221091046
   Web of Science ®Google Scholar
• Debureaux PE, Kulasekararaj AG, Cacace F, et al. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant. 2021;56(10):2600–2602. doi:10.1038/s41409-021-01372-0
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786–6792. doi:10.1182/blood-2011-02-333997
   PubMed Web of Science ®Google Scholar
• Loschi M, Porcher R, Barraco F, et al. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. Am J Hematol. 2016;91(4):366–370. doi:10.1002/ajh.24278
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123–4128. doi:10.1182/blood-2007-06-095646
   PubMed Web of Science ®Google Scholar
• Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243. doi:10.1056/NEJMoa061648
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840–1847. doi:10.1182/blood-2007-06-094136
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Brodsky RA, Ortiz S, et al. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies. Br J Haematol. 2020;191(3):476–485. doi:10.1111/bjh.16711
   PubMed Web of Science ®Google Scholar
• Kulasekararaj A, Brodsky R, Griffin M, et al. Long-term complement inhibition and survival outcomes in patients with paroxysmal nocturnal hemoglobinuria: an interim analysis of the ravulizumab clinical trials. Hemasphere. 2022;6:706–707. doi:10.1097/01.HS9.0000846132.33920.32
   Google Scholar
• Roth A, Nishimura JI, Nagy Z, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020;135(12):912–920. doi:10.1182/blood.2019003399
   PubMed Web of Science ®Google Scholar
• Roth A, Ichikawa S, Ito Y, et al. Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: long-term results from the phase I/II COMPOSER trial. Eur J Haematol. 2023;111(2):300–310. doi:10.1111/ejh.14011
   PubMed Web of Science ®Google Scholar
• Latuszek A, Liu Y, Olsen O, et al. Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020;15(5):e0231892. doi:10.1371/journal.pone.0231892
   PubMed Web of Science ®Google Scholar
• Badri P, Jiang X, Borodovsky A, et al. Pharmacokinetic and pharmacodynamic properties of cemdisiran, an RNAi therapeutic targeting complement component 5, in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365–378. doi:10.1007/s40262-020-00940-9
   PubMed Web of Science ®Google Scholar
• Nishimura JI, Ando K, Masuko M, et al. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2022;107(6):1483–1488. doi:10.3324/haematol.2020.265868
   PubMed Web of Science ®Google Scholar
• Kulasekararaj A, Brodsky R, Kulagin A, Jang JH. Biosimilars in rare diseases: a focus on paroxysmal nocturnal hemoglobinuria. Haematologica. 2023;108(5):1232–1243. doi:10.3324/haematol.2022.281562
   PubMed Web of Science ®Google Scholar
• Kulasekararaj A, Lanza F, Arvanitakis A, et al. Efficacy and safety of biosimilar candidate ABP 959 as compared with eculizumab reference product in paroxysmal nocturnal hemoglobinuria. Blood. 2022;140(1):8660–8662. doi:10.1182/blood-2022-166722
   Google Scholar
• Chow V, Pan J, Chien D, Mytych DT, Hanes V. A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris((R))) in healthy male subjects. Eur J Haematol. 2020;105(1):66–74. doi:10.1111/ejh.13411
   PubMed Web of Science ®Google Scholar
• Lee HA, Jang H, Jeong D, Kim Y, Fuhr R. A randomized, double-blind, three-arm, parallel group, single-dose Phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects. Int J Clin Pharmacol Ther. 2022;60(6):269–279. doi:10.5414/CP204176
   PubMed Web of Science ®Google Scholar
• Gusarova V, Degterev M, Lyagoskin I, et al. Analytical and functional similarity of biosimilar Elizaria(R) with eculizumab reference product. J Pharm Biomed Anal. 2022;220:115004. doi:10.1016/j.jpba.2022.115004
   PubMed Web of Science ®Google Scholar
• Mastellos DC, Yancopoulou D, Kokkinos P, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015;45(4):423–440. doi:10.1111/eci.12419
   PubMed Web of Science ®Google Scholar
• Lee JW, Brodsky RA, Nishimura JI, Kulasekararaj AG. The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments. Expert Rev Clin Pharmacol. 2022;15(7):851–861. doi:10.1080/17512433.2022.2109462
   PubMed Web of Science ®Google Scholar
• Panse J, Wilson K, Fishman J, et al. Fatigue and health-related quality of life in paroxysmal nocturnal haemoglobinuria: a post hoc analysis of the pegcetacoplan PEGASUS trial data. Eur J Haematol. 2023;111(1):72–83. doi:10.1111/ejh.13969
   PubMed Web of Science ®Google Scholar
• Patriquin CJ, Bogdanovic A, Griffin M, et al. Long-Term Safety and Efficacy of Pegcetacoplan Treatment in Adults with Paroxysmal Nocturnal Hemoglobinuria. Blood. 2022;140(1):2921–2923. doi:10.1182/blood-2022-163625
   Google Scholar
• M G, Kelly R, Deeren D, et al. Intensive pegcetacoplan dosing in the management of acute hemolysis as part of the 307 open-label extension study. presented at: American Society of Hematology; 2022; New Orleans. Available from: https://ashpublications.org/blood/article/140/Supplement%201/2937/492951/Intensive-Pegcetacoplan-Dosing-in-the-Management. Accessed December 02, 2023.
   Google Scholar
• Griffin M, Muus P, Munir T, et al. Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria. Blood. 2023;141(1):116–120. doi:10.1182/blood.2022017266
   PubMed Web of Science ®Google Scholar
• Risitano AM, Roth A, Soret J, et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol. 2021;8(5):e344–e354. doi:10.1016/S2352-3026(21)00028-4
   PubMed Web of Science ®Google Scholar
• Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion Independence in all treatment-naïve PNH patients. 2023. Available from: https://www.novartis.com/news/media-releases/novartis-phase-iii-appoint-pnh-trial-shows-investigational-oral-monotherapy-iptacopan-improves-hemoglobin-near-normal-levels-leading-transfusion-independence-all-treatment-naive-pnh-patients. Accessed December 02, 2023.
   Google Scholar
• Risitano A, Han B, Ueda Y, et al. Oral complement factor B inhibitor iptacopan monotherapy improves hemoglobin to normal/near-normal levels in paroxysmal nocturnal hemoglobinuria patients naïve to complement inhibitors: phase III APPOINT-PNH trial; 2023.
   Google Scholar
• Barratt J, Weitz I. Complement factor D as a strategic target for regulating the alternative complement pathway. Front Immunol. 2021;12:712572. doi:10.3389/fimmu.2021.712572
   PubMed Web of Science ®Google Scholar
• Kulasekararaj A, Füreder W, McDonald A, et al. Factor D inhibition with oral bcx9930 leads to sustained control of hemolysis and symptoms over 48 weeks in subjects with paroxysmal nocturnal hemoglobinuria inadequately controlled on c5 inhibitors. Hemasphere. 2022;6:720–721. doi:10.1097/01.HS9.0000846188.51290.75
   Google Scholar
• McDonald A, Malherbe JL, Kulasekararaj A, et al. Factor D inhibition with oral bcx9930 monotherapy leads to sustained control of hemolysis and symptoms over 48 weeks in subjects with paroxysmal nocturnal hemoglobinuria naïve to c5 inhibitors. Hemasphere. 2022;6:719–720. doi:10.1097/01.HS9.0000846184.35066.7a
   Google Scholar
• BioCryst discontinues development of BCX9930 and shifts focus to potential once-daily, oral factor D inhibitor, BCX10013; 2022. Available from: https://ir.biocryst.com/news-releases/news-release-details/biocryst-discontinues-development-bcx9930-and-shifts-focus. Accessed December 02, 2023.
   Google Scholar
• Kulasekararaj AG, Risitano AM, Maciejewski JP, et al. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood. 2021;138(20):1928–1938. doi:10.1182/blood.2021011388
   PubMed Web of Science ®Google Scholar
• Kira pharmaceuticals announces first cohort of patients dosed in phase 2 study of KP104 in paroxysmal nocturnal hemoglobinuria (PNH); 2022. Available from: https://www.prnewswire.com/news-releases/kira-pharmaceuticals-announces-first-cohort-of-patients-dosed-in-phase-2-study-of-kp104-in-paroxysmal-nocturnal-hemoglobinuria-pnh-301689797.html. Accessed December 02, 2023.
   Google Scholar
• Griffin M, Hillmen P, Munir T, et al. Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. Haematologica. 2019;104(3):e94–e96. doi:10.3324/haematol.2018.198846
   PubMed Web of Science ®Google Scholar
• Almeida AM, Bedrosian C, Cole A, et al. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry. Intern Med J. 2017;47(9):1026–1034. doi:10.1111/imj.13523
   PubMed Web of Science ®Google Scholar
• CADTH. Ravulizumab; 2022. Available from: https://www.cadth.ca/ravulizumab-0. Accessed 04 December 2023.
   Google Scholar
• de Castro C, Grossi F, Weitz IC, et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol. 2020;95(11):1334–1343. doi:10.1002/ajh.25960
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Lee JW, Nishimura JI, Szer J. Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria? Br J Haematol. 2022;196(2):264–265. doi:10.1111/bjh.17860
   PubMed Web of Science ®Google Scholar
• Lee JW, Jang JH, Kim JS, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013;97(6):749–757. doi:10.1007/s12185-013-1346-4
   PubMed Web of Science ®Google Scholar
• Risitano AM, Kulasekararaj AG, Lee JW, et al. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria. Haematologica. 2021;106(12):3188–3197. doi:10.3324/haematol.2020.261826
   PubMed Web of Science ®Google Scholar
• Jang JH, Pavani R, Aurand L, et al. A phase 2, randomized trial evaluating the safety and efficacy of pozelimab and cemdisiran in patients with paroxysmal nocturnal hemoglobinuria. Presented at: European Hematology Association; 2023; Frankfurt, Germany. Available from: https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eha/temp/eha23_abstract_bodies/P782.pdf. Accessed December 02, 2023.
   Google Scholar
• Summary Safety Review - SOLIRIS (eculizumab) and BEXSERO (Multicomponent Meningococcal B Vaccine [recombinant, adsorbed]) - Assessing the Potential Risk of Hemolysis and Low Hemoglobin in Patients Treated with Soliris and Vaccinated with Bexsero; 2016.
   Google Scholar
• Granoff DM, Kim H, Topaz N, MacNeil J, Wang X, McNamara LA. Differential effects of therapeutic complement inhibitors on serum bactericidal activity against non-groupable meningococcal isolates recovered from patients treated with eculizumab. Haematologica. 2019;104(8):e340–e344. doi:10.3324/haematol.2018.209692
   PubMed Web of Science ®Google Scholar
• Konar M, Granoff DM. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood. 2017;130(7):891–899. doi:10.1182/blood-2017-05-781450
   PubMed Web of Science ®Google Scholar
• Patriquin CJ, Kulasekararaj A, Peffault de Latour R, et al. Prophylactic antibiotic use and risk of meningococcal infections in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) treated with eculizumab who received meningococcal vaccination: results from the international PNH registry. Blood. 2019;134(1):4802. doi:10.1182/blood-2019-127005
   Google Scholar
• Jodele S, Dandoy CE, Danziger-Isakov L, et al. Terminal complement blockade after hematopoietic stem cell transplantation is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016;22(7):1337–1340. doi:10.1016/j.bbmt.2016.03.032
   PubMed Web of Science ®Google Scholar
• Luzzatto L, Hyry HI, Schieppati A, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392(10149):791–794. doi:10.1016/S0140-6736(18)31069-9
   PubMed Web of Science ®Google Scholar
• Kulasekararaj AG, Kuter DJ, Griffin M, Weitz IC, Roth A. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: differences between terminal and proximal complement inhibition. Blood Rev. 2023;59:101041. doi:10.1016/j.blre.2023.101041
   PubMed Web of Science ®Google Scholar